HUTCHMED China Ltd (HCM) - Total Liabilities
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has total liabilities worth GBX534.02 Million GBX (≈ $64.97K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HUTCHMED China Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how HUTCHMED China Ltd's total liabilities have evolved over time, based on quarterly financial data. See HUTCHMED China Ltd (HCM) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
HUTCHMED China Ltd Competitors by Total Liabilities
The table below lists competitors of HUTCHMED China Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VentriPoint Diagnostics Ltd
V:VPT
|
Canada | CA$5.03 Million |
|
Kamdhenu Ventures Limited
NSE:KAMOPAINTS
|
India | Rs1.11 Billion |
|
Quickfee Ltd
AU:QFE
|
Australia | AU$68.83 Million |
|
Ping An Biomedical Co., Ltd.
NASDAQ:PASW
|
USA | $23.17 Million |
|
IXUP Ltd
AU:IXU
|
Australia | AU$2.67 Million |
|
China Times Publishing Co
TWO:8923
|
Taiwan | NT$434.12 Million |
|
Cassius Mining Ltd
AU:CMD
|
Australia | AU$685.20K |
|
Dyandra Media International PT
JK:DYAN
|
Indonesia | Rp453.34 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down HUTCHMED China Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is HUTCHMED China Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED China Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED China Ltd (2005–2024)
The table below shows the annual total liabilities of HUTCHMED China Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX502.34 Million ≈ $61.12K |
-6.35% |
| 2023-12-31 | GBX536.39 Million ≈ $65.26K |
+36.63% |
| 2022-12-31 | GBX392.57 Million ≈ $47.77K |
+17.84% |
| 2021-12-31 | GBX333.15 Million ≈ $40.53K |
+62.38% |
| 2020-12-31 | GBX205.17 Million ≈ $24.96K |
+34.79% |
| 2019-12-31 | GBX152.22 Million ≈ $18.52K |
+26.99% |
| 2018-12-31 | GBX119.86 Million ≈ $14.58K |
+6.11% |
| 2017-12-31 | GBX112.97 Million ≈ $13.74K |
-18.36% |
| 2016-12-31 | GBX138.38 Million ≈ $16.84K |
+8.55% |
| 2015-12-31 | GBX127.48 Million ≈ $15.51K |
+28.69% |
| 2014-12-31 | GBX99.06 Million ≈ $12.05K |
+22.55% |
| 2013-12-31 | GBX80.83 Million ≈ $9.83K |
-35.76% |
| 2012-12-31 | GBX125.82 Million ≈ $15.31K |
+7.13% |
| 2011-12-31 | GBX117.44 Million ≈ $14.29K |
+28.89% |
| 2010-12-31 | GBX91.12 Million ≈ $11.09K |
+73.71% |
| 2009-12-31 | GBX52.45 Million ≈ $6.38K |
+56.43% |
| 2008-12-31 | GBX33.53 Million ≈ $4.08K |
+11.93% |
| 2007-12-31 | GBX29.96 Million ≈ $3.64K |
+29.89% |
| 2006-12-31 | GBX23.06 Million ≈ $2.81K |
-74.63% |
| 2005-12-31 | GBX90.89 Million ≈ $11.06K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more